1. ALLA AKTIER
  2. NYHETER
  3. NEOLA MEDICAL

Neola Medical

Nyheter Neola Medical Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Neola Medical’s CEO highlights recent progress in autumn 2025 investor letter

Neola Medical continues to advance through the clinical phase, with its clinical pilot study on preterm born babies in Sweden now at the halfway point. During the autumn, the company strengthened its leadership team with the appointment of a Clinical Director, expanded its intellectual property portfolio with a new European patent, and CEO Hanna Sjöström participated in the Stanford Impact1 CEO Summit, further building Neola Medical’s international network of leading clinicians, experts, and investors as the company advances toward market authorization.

“Strengthening our leadership team, expanding our patent portfolio, and deepening our international network through Stanford Impact1 are all important steps as we advance toward market authorization and continue our mission to improve outcomes for preterm born babies,” says CEO Hanna Sjöström.

Read more in the investor letter autumn 2025, attached to this press release and available on the company’s website www.neolamedical.com

For further information, contact:
Hanna Sjöström, CEO
e-mail: hanna.sjostrom@neolamedical.com

About Neola Medical
Neola Medical AB (publ) develops an innovative medical technology device for non-invasive, continuous lung monitoring and real-time alerts of potentially life-threatening lung complications in preterm born babies. By enabling instant detection, the technology aims to support earlier intervention, improve clinical decision-making, enhance long-term outcomes, and ultimately contribute to saving lives. The patented, cutting-edge technology was developed at Lund University in Sweden and is based on a spectroscopic method that measures changes in lung volume and oxygen gas concentration. Neola Medical builds on Sweden’s longstanding legacy of medical technology innovation and contributions to global health care. Neola Medical was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at www.neolamedical.com. The company’s Certified Adviser is FNCA Sweden AB.

Attachments
Neola Medical’s CEO highlights recent progress in autumn 2025 investor letter
Neola Medical Investor Letter Autumn 2025

Datum 2025-10-01, kl 07:00
Källa MFN
Bifogade filer
Neola Medical’s CEO highlights recent progress in autumn 2025 investor letter
Neola Medical Investor Letter Autumn 2025